Statement: There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.
Primary_evidence: Outcome Measurement:    Number of Subjects With Clinical Benefit   Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.   Time frame: Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV) Results 1:    Arm/Group Title: Exemestane (Exemestane Alone)   Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily)   Overall Number of Participants Analyzed: 49   Measure Type: Number   Unit of Measure: participants  24 Results 2:    Arm/Group Title: Combination (Exemestane + Celecoxib)   Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)   Overall Number of Participants Analyzed: 51   Measure Type: Number   Unit of Measure: participants  24